Idebenone and coenzyme Q10 are novel PPARα/γ ligands, with potential for treatment of fatty liver diseases

• Main Authors: Jens Tiefenbach (Author), Lilia Magomedova (Author), Jiabao Liu (Author), Arkadiy A. Reunov (Author), Ricky Tsai (Author), Neena S. Eappen (Author), Rebecca A. Jockusch (Author), Corey Nislow (Author), Carolyn L. Cummins (Author), Henry M. Krause (Author)
• Format: Book
• Published: The Company of Biologists, 2018-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Current peroxisome proliferator-activated receptor (PPAR)-targeted drugs, such as the PPARγ-directed diabetes drug rosiglitazone, are associated with undesirable side effects due to robust agonist activity in non-target tissues. To find new PPAR ligands with fewer toxic effects, we generated transge...